Breast Imaging

What Is the Next Step for a Suspicious Axillary Node in Breast Cancer Staging?

·
What Is the Next Step for a Suspicious Axillary Node in Breast Cancer Staging?

A 54-year-old patient’s new diagnosis of invasive ductal carcinoma on core biopsy is confirmed. During the initial staging workup, the diagnostic mammogram and subsequent axillary ultrasound reveal a 1.5 cm lymph node with cortical thickening and effacement of the fatty hilum. The multidisciplinary tumor board is considering neoadjuvant systemic therapy, but the treatment regimen depends on definitively staging the axilla. As the ordering clinician, you must decide the most direct and accurate next step to confirm or rule out nodal metastasis. This article details the clinical workflow for this exact scenario, where the American College of Radiology (ACR) has determined that a specific procedure is Usually Appropriate.

Who Fits This Clinical Scenario for Axillary Staging?

This guidance applies to any adult patient—female, male, transfeminine (male-to-female), or transmasculine (female-to-male)—with a new, biopsy-proven diagnosis of breast cancer who has not yet started treatment. The key feature is the identification of one or more suspicious axillary lymph nodes on initial imaging, whether that’s mammography, digital breast tomosynthesis, ultrasound, or breast Magnetic Resonance Imaging (MRI). A “suspicious” node typically exhibits features like loss of the fatty hilum, a rounded shape, or focal or diffuse cortical thickening.

This workflow is specifically for pre-treatment staging. It does not apply to patients who:

  • Have a clinically negative axilla with no suspicious nodes on imaging. Their pathway typically involves sentinel lymph node biopsy at the time of surgery.
  • Are already undergoing neoadjuvant systemic therapy. Evaluating response to treatment is a different clinical question with its own imaging pathway.
  • Present with palpable, bulky axillary adenopathy (clinically node-positive), where the need for tissue confirmation is clear but the downstream surgical implications may differ.

What Diagnoses Are You Working Up with an Axillary Biopsy?

When ordering a biopsy for a suspicious axillary node, the primary goal is to confirm or exclude metastasis, which is a critical factor for staging and treatment planning. However, other less common diagnoses are also on the differential.

Metastatic Breast Carcinoma
This is the most common and clinically significant finding. Confirming nodal metastasis upstages the patient (to at least Stage II) and is a primary indication for considering neoadjuvant systemic therapy before surgery. Histologic confirmation provides crucial prognostic information and can guide the intensity and type of systemic therapy.

Reactive Lymphadenopathy
Benign enlargement of lymph nodes can occur due to systemic inflammation or infection. While ultrasound features can often distinguish reactive from malignant nodes, there is significant overlap in appearance. A biopsy is necessary for a definitive diagnosis when the morphology is suspicious for malignancy.

Lymphoma
While less common, a new diagnosis of lymphoma can occasionally present as axillary adenopathy. If the core biopsy reveals lymphoma rather than metastatic carcinoma, the patient’s entire treatment plan will be redirected to a hematologist-oncologist for a completely different therapeutic approach.

Granulomatous Disease
Rare causes like sarcoidosis or tuberculosis can cause enlarged axillary nodes that mimic malignancy on imaging. A biopsy revealing non-caseating or caseating granulomas would prompt a workup for these systemic conditions, which are managed separately from the breast cancer.

Why Is US-Guided Core Biopsy the Recommended Study for a Suspicious Axillary Node?

For a patient with known breast cancer and a suspicious axillary node found on initial imaging, the ACR designates US-guided core biopsy axillary node as Usually Appropriate. This procedure is the most direct and reliable path to a definitive tissue diagnosis, which is essential for accurate staging.

Ultrasound provides excellent real-time visualization of the needle, ensuring accurate targeting of the most suspicious portion of the node while avoiding adjacent blood vessels. A core biopsy retrieves a small cylinder of tissue, which crucially preserves the tissue architecture. This histologic sample allows the pathologist to confidently distinguish metastatic carcinoma from other causes like lymphoma or reactive changes. Furthermore, a core sample provides sufficient material for ancillary studies, such as determining the hormone receptor (ER/PR) and HER2 status of the metastasis, which can sometimes differ from the primary tumor and influence therapy decisions.

US-guided fine needle aspiration (FNA) biopsy axillary node is also rated as Usually Appropriate. However, FNA provides a collection of cells (cytology) rather than intact tissue. While often sufficient to confirm malignancy, it can have a higher false-negative rate and may not provide enough material for the ancillary receptor testing that is standard in modern breast cancer care. For these reasons, core biopsy is often preferred by many institutions.

Alternative imaging studies are not recommended at this stage:

  • Mammography diagnostic and Digital breast tomosynthesis diagnostic are rated Usually not appropriate. These are imaging tools, not biopsy methods. The suspicious node has already been identified; repeating imaging without obtaining a tissue sample does not advance the workup.
  • MRI breast without and with IV contrast is also rated Usually not appropriate for this specific question. The goal is no longer to characterize the node’s appearance but to obtain a pathologic diagnosis.

Both US-guided biopsy procedures are extremely safe and involve no ionizing radiation (0 mSv). Once you’ve decided on US-guided core biopsy, our protocol guide covers the technique, patient preparation, and reporting principles: Breast Biopsy (Ultrasound-Guided).

What’s Next After Axillary Node Biopsy? Downstream Workflow

The pathology result from the axillary node biopsy directly influences the subsequent treatment plan. The workflow diverges based on whether the node is positive or negative for metastatic disease.

If the Biopsy is Positive for Metastasis
A positive result confirms node-positive (Stage II or III) disease. This finding typically makes the patient a candidate for neoadjuvant systemic therapy (chemotherapy, targeted therapy, and/or endocrine therapy) before any surgery. During the biopsy, a small metallic clip is placed in the sampled node. This clip allows the surgeon to identify and potentially remove that specific node (targeted axillary dissection) after neoadjuvant treatment, even if the therapy shrinks the node and makes it appear normal on later imaging.

If the Biopsy is Negative for Metastasis
A benign result (e.g., reactive lymphoid tissue) suggests the axilla is pathologically node-negative. The patient would then typically proceed to surgery, which would include a sentinel lymph node biopsy (SLNB) to sample the first-draining nodes. If the pre-test suspicion on imaging was very high, the multidisciplinary team may discuss biopsying a second suspicious node, if one exists, before concluding the axilla is negative.

If the Biopsy is Indeterminate
In rare cases, the result may be atypical or indeterminate. This requires discussion at a multidisciplinary tumor board. The decision may be to repeat the core biopsy, perform an FNA for corroborating cytology, or proceed with an excisional biopsy of the node.

Pitfalls to Avoid (and When to Get Help)

Navigating this step in breast cancer staging requires careful attention to detail to ensure the treatment plan is based on accurate information. Common pitfalls include:

  • Sampling the Wrong Node: It is critical for the radiologist to target the most morphologically suspicious node identified on the initial diagnostic imaging.
  • Forgetting to Place a Clip: Failure to place a biopsy clip in a node that proves to be malignant is a significant pitfall. This makes it difficult or impossible to perform a targeted axillary dissection after neoadjuvant therapy.
  • Insufficient Sample: Obtaining too few cores or a non-diagnostic sample can lead to a false-negative result and require a repeat procedure, delaying treatment.
  • Relying on FNA Alone: While FNA is fast, it may not provide the comprehensive histologic and molecular data needed for optimal neoadjuvant therapy planning.

If the biopsy results are discordant with the imaging findings (e.g., a highly suspicious node returns as benign), escalate the case for review at a multidisciplinary tumor board before finalizing the surgical plan.

Related ACR Topics and Tools

This article covers one specific decision point in breast cancer staging. For a broader view of imaging throughout the treatment course, and for tools to help with ordering and patient communication, the following resources are available.

Frequently Asked Questions

Why not just perform a sentinel lymph node biopsy (SLNB) instead of a pre-treatment needle biopsy?

Performing a needle biopsy first to confirm axillary metastasis before starting treatment is crucial for planning. If the node is positive, the patient can receive neoadjuvant systemic therapy, which can shrink the cancer in both the breast and axilla, potentially allowing for less extensive axillary surgery later. An upfront SLNB is a surgical procedure and is typically reserved for patients who are clinically and radiologically node-negative.

What is the main difference between core biopsy and fine-needle aspiration (FNA) for this scenario?

A core biopsy obtains a solid piece of tissue (histology), which preserves the cellular architecture and provides more material for ancillary testing like hormone receptor and HER2 status. FNA retrieves a sample of individual cells (cytology). While both are rated ‘Usually Appropriate’ by the ACR, core biopsy is often preferred because it provides a more definitive diagnosis and the comprehensive data needed to guide modern systemic therapies.

What happens if ultrasound can’t identify the suspicious node seen on mammography or MRI?

If a suspicious node is not visible on ultrasound, alternative guidance methods may be necessary. For a node seen only on MRI, an MRI-guided biopsy can be performed. If it’s seen only on mammography (e.g., due to calcifications), a stereotactic-guided biopsy may be an option, though this is less common for nodes. The case should be discussed with the breast radiologist to determine the best localization and biopsy technique.

Is it always necessary to place a clip in the biopsied lymph node?

Yes, if a node is being biopsied for pre-treatment staging, placing a clip is standard of care. If the node is positive and the patient receives neoadjuvant therapy, the cancer in the node may be completely eradicated, making it invisible on future imaging. The clip is the only reliable way for the surgeon to find and remove that specific, previously-cancerous node after treatment is complete.

Does this axillary staging workflow apply to inflammatory breast cancer (IBC)?

Yes, but with added urgency. IBC is an aggressive form of breast cancer that is by definition at least Stage III, and axillary lymph node involvement is nearly universal. Tissue confirmation of a suspicious axillary node is still a standard part of the initial workup, which must be completed rapidly to allow for the prompt initiation of neoadjuvant systemic therapy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026